These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 17444026

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. 2004 update--180-day exclusivity under the Hatch-Waxman amendments to the federal Food, Drug, and Cosmetic Act.
    Lietzan EK.
    Food Drug Law J; 2004; 59(4):459-63. PubMed ID: 15875350
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ.
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract] [Full Text] [Related]

  • 5. A brief history of 180-day exclusivity under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act.
    Lietzan EK.
    Food Drug Law J; 2004; 59(2):287-323. PubMed ID: 15298013
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
    Srivastava D.
    Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
    [No Abstract] [Full Text] [Related]

  • 9. FDA's role in making exclusivity determinations.
    Dickinson EH.
    Food Drug Law J; 1999; 54(2):195-203. PubMed ID: 11758573
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2003 Jun 18; 68(117):36675-712. PubMed ID: 12814136
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The History and Political Economy of the Hatch-Waxman Amendments.
    Lietzan E.
    Seton Hall Law Rev; 2019 Jun 18; 49(1):53-127. PubMed ID: 30557922
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT.
    Mich Law Rev; 2015 Jun 18; 114(1):107-36. PubMed ID: 26394458
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity.
    Morag-Sela T, Cohn I, Kowalski TJ, Jarecki-Black J, Clyde-Watson Z.
    Nat Biotechnol; 2004 Dec 18; 22(12):1591-2. PubMed ID: 15583670
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.